Anastrozole: Drug information

(For additional information see "Anastrozole: Patient drug information")

For abbreviations, symbols, and age group definitions used in Lexicomp (show table)

Brand Names: US

Arimidex

Brand Names: Canada

ACH-Anastrozole;
AG-Anastrozole;
APO-Anastrozole;
Arimidex;
BIO-Anastrozole;
CCP-Anastrozole [DSC];
JAMP-Anastrozole;
Mar-Anastrozole;
MINT-Anastrozole;
NAT-Anastrozole;
PMS-Anastrozole;
RIVA-Anastrozole;
SANDOZ Anastrozole;
TARO-Anastrozole;
TEVA-Anastrozole

Pharmacologic Category

Antineoplastic Agent, Aromatase Inhibitor

Dosing: Adult

Breast cancer, advanced

Breast cancer, advanced: Postmenopausal patients: Oral: 1 mg once daily; continue until tumor progression or unacceptable toxicity.

Breast cancer, advanced, estrogen receptor-positive, HER2-negative

Breast cancer, advanced, estrogen receptor-positive, HER2-negative (off-label combination):

Postmenopausal patients: Oral: 1 mg once daily (in combination with abemaciclib) until disease progression or unacceptable toxicity (Ref). Aromatase inhibitors have also been used in combination with palbociclib and ribociclib (Ref).

Premenopausal or perimenopausal patients: Oral: 1 mg once daily (in combination with ribociclib [and the luteinizing hormone-releasing hormone (LHRH) agonist goserelin]) until disease progression or unacceptable toxicity (Ref).

Breast cancer, early, adjuvant therapy

Breast cancer, early, adjuvant therapy:

Postmenopausal patients: Oral: 1 mg once daily.

Premenopausal patients with high-risk disease (off-label use): Oral: 1 mg once daily (in combination with ovarian function suppression) (Ref).

Duration of therapy: The American Society of Clinical Oncology (ASCO) guidelines for adjuvant endocrine therapy of hormone-receptor positive breast cancer (focused update) recommend a duration of 5 to 10 years of adjuvant endocrine therapy; some patients may be appropriate candidates for extended aromatase inhibitor (AI) therapy for up to a total of 10 years based on disease recurrence risk and nodal disease status. Refer to the guidelines for specific recommendations based on menopausal status and tolerability (Ref). In a phase 3 study with another AI (letrozole), treatment with an additional 5 years of AI therapy (for a total of 10 years of AI therapy) demonstrated a significantly improved rate of disease-free survival and a decreased risk of disease recurrence and contralateral breast cancer (when compared to placebo), although overall survival was not significantly different between groups and bone-related adverse events occurred more frequently with letrozole versus placebo (Ref).

Breast cancer in male patients, hormone receptor–positive

Breast cancer in male patients, hormone receptor–positive (off-label use): Note: Should be used in combination with a gonadotropin-releasing hormone agonist/antagonist (Ref).

Adjuvant t herapy (alternative agent): May be used as adjuvant therapy in male patients with hormone receptor–positive breast cancer with a contraindication to tamoxifen. ASCO guidelines for management of male breast cancer recommend an initial duration of 5 years of adjuvant endocrine therapy; if there still is a high risk of recurrence, five additional years of endocrine therapy may be offered if the initial 5 years of adjuvant therapy have been completed and tolerated (Ref).

Advanced or metastatic disease: Oral: 1 mg once daily until disease progression or unacceptable toxicity (Ref). Endocrine therapy for males with advanced or metastatic, HR+, HER2-negative breast cancer may be sequenced as in females (Ref).

Breast cancer, risk reduction

Breast cancer, risk reduction (off-label use): Postmenopausal patients ≥40 years of age: Oral: 1 mg once daily for 5 years (Ref).

Endometrial or uterine cancer, recurrent or metastatic

Endometrial or uterine cancer, recurrent or metastatic (off-label use): Oral: 1 mg once daily (Ref).

Ovarian cancer, recurrent

Ovarian cancer, recurrent (off-label use): Oral: 1 mg once daily until disease progression or unacceptable toxicity (Ref).

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Adult

Kidney impairment: No dosage adjustment necessary.

Hemodialysis: No dosage adjustment necessary (Ref).

Dosing: Hepatic Impairment: Adult

Mild to moderate impairment or stable hepatic cirrhosis: No dosage adjustment necessary.

Severe hepatic impairment: There are no dosage adjustments provided in the manufacturer's labeling. However, some sources do not recommend anastrozole use in severe impairment (Ref).

Dosing: Older Adult

Refer to adult dosing.

Adverse Reactions (Significant): Considerations

Bone mineral density loss/increased fracture risk

Anastrozole is associated with a decreased bone mineral density (BMD); decreases (from baseline) in total hip BMD (~7% loss after 5 years) and lumbar spine BMD (~6% loss after 5 years) have been reported (Ref). Anastrozole has been linked to bone resorption in postmenopausal females; therefore, an increased risk of osteoporosis and bone fracture should be considered when administering treatment (Ref).

Mechanism: Time-related; anastrozole decreases plasma estrogen levels up to 94% in postmenopausal women with estrogen-positive breast cancer. Low levels of estrogen have been linked to bone resorption leading to decreased BMD, especially at the lumbar spine (LS) and hip. This results in increased risk of osteoporosis and fracture (Ref).

Onset: Delayed; bone loss in LS occurred during the first 2 years of treatment with no additional loss seen in years 2 to 5. No slowing of bone loss occurred in the total hip BMD (Ref). There was a statistically significant LS BMD increase in the 2 years after discontinuing 5 years of treatment (Ref).

Risk factors:

• Longer durations of aromatase inhibitors (more than 3 years of therapy) (Ref).

• Preexisting known risk factors for BMD loss, osteoporosis, and fracture (includes preexisting osteopenia, age >65 years, years since menopause, body mass index <20 kg/m², personal/family history, chronic glucocorticoid use >6 months, prior fragility fracture history, low bone mineral density, rheumatoid arthritis, and smoking) (Ref).

Ischemic cardiovascular events

Ischemic heart disease has been reported, with an increased incidence of ischemic cardiovascular events in patients with preexisting ischemic heart disease (Ref). Angina pectoris and acute myocardial infarction (MI) have occurred.

Mechanism: Non-dose-related; idiosyncratic. Aromatase inhibitors (AIs), such as anastrozole, reduce the protective effects of estrogen, consequently leading to increases in vasoconstriction and atherosclerosis. Additionally, there is a dysregulation of lipid metabolism and potential risk of hyperlipidemia. Together, these factors may increase the risk of cardiovascular disease (CVD) in patients receiving AI for breast cancer treatment (Ref).

Timing: Varied; cardiac ischemia may occur at any time during treatment (Ref).

Risk factors:

• Preexisting CVD, including ischemic heart disease, or risk factors associated with CVD (Ref). In a large SEER-Medicare cohort evaluating MI risk with adjuvant hormone therapy, several preexisting conditions were associated with MI including diabetes with complications, heart failure, prior MI, coronary artery disease, and peripheral vascular disease. In patients with prior history of MI, hazard ratio was nearly 3-fold higher (Ref).

• Longer durations of AI therapy (more than 3 years of therapy) are associated with 18% to 26% increased risk of cardiovascular disease (Ref).

Musculoskeletal effects

Musculoskeletal effects, including new onset or exacerbation of existing arthralgia, joint stiffness, and/or ostealgia, may occur with anastrozole (Ref); pain may be severe and/or continuous (Ref). Aromatase inhibitor-induced arthralgia (AIA) presents with symmetrical joint pains most commonly affecting hands, wrists, and knees (Ref). Trigger finger and carpal tunnel syndrome may also be common complaints (Ref). These adverse reactions may significantly affect quality of life and the risk of treatment nonadherence or discontinuation should be considered; treatment discontinuation due to musculoskeletal symptoms has been reported between 5% to 20% (Ref).

Mechanism: Non-dose-related; idiosyncratic. Exact mechanism is unknown; however, multiple mechanisms have been proposed involving estrogen depletion either as a direct or indirect cause. Proposed estrogen depletion mechanisms include direct local effects on joint tissues, increased inflammatory parameters such as IL-6 indirectly affecting central and peripheral nociception (Ref), decreased estradiol leading to a decrease in endogenous opioid levels (Ref), collagen degradation, and impaired regulation of cartilage structure (Ref).

Onset: Varied; the median time to onset of symptoms is 1.6 to 2 months with a range of 1 week to >10 months. Symptoms have been shown to peak ~6 months after initiation of treatment (Ref). By 18 months, 75% of patients in the ATAC trial had experienced significant improvement of their symptoms (Ref).

Risk factors:

• Prior menopausal hormone therapy or previous chemotherapy (Ref).

• Certain CYP19A1 single nucleotide polymorphisms (SNPs) have been associated with increased arthralgia symptoms and/or association with discontinuation of therapy due to intolerable arthralgia (Ref)

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.

>10%:

Cardiovascular: Angina pectoris (2%; 12% in patients with preexisting ischemic heart disease) (table 1), hypertension (5% to 13%), ischemic heart disease (4%; increased incidence of ischemic cardiovascular events seen in patients with preexisting ischemic heart disease: 17%) (table 2), vasodilation (25% to 36%)

**Anastrozole: Adverse Reaction: Angina Pectoris**
Drug (Anastrozole)	Comparator (Tamoxifen)	Indication	Number of Patients (Anastrozole)	Number of Patients (Tamoxifen)	Comments
2%	2%	Breast cancer	3,092	3,094	N/A
12%	5%	Breast cancer	216	249	In patients with preexisting ischemic heart disease

**Anastrozole: Adverse Reaction: Ischemic Heart Disease**
Drug (Anastrozole)	Comparator (Tamoxifen)	Indication	Number of Patients (Anastrozole)	Number of Patients (Tamoxifen)	Comments
4%	3%	Breast cancer	3,092	3,094	N/A
17%	10%	Breast cancer	216	249	In patients with preexisting ischemic heart disease

Dermatologic: Skin rash (6% to 11%)

Endocrine & metabolic: Hot flash (12% to 36%)

Gastrointestinal: Gastrointestinal distress (29% to 34%), nausea (11% to 19%), vomiting (≤13%)

Nervous system: Depression (5% to 13%), fatigue (≤19%), headache (9% to 13%), mood disorder (19%), pain (11% to 17%)

Neuromuscular & skeletal: Arthralgia (15%; literature suggests incidence as high as 36%) (Howell 2005) (table 3), arthritis (17%) (table 4), asthenia (≤19%), back pain (10% to 12%) (table 5), ostealgia (7% to 11%) (table 6), osteoporosis (11%; literature suggests incidence as high as 20% in patients with preexisting osteopenia after 3- to 6-years of anastrazole) (van Hellemond 2019) (table 7)

**Anastrozole: Adverse Reaction: Arthralgia**
Drug (Anastrozole)	Comparator (Tamoxifen)	Indication	Number of Patients (Anastrozole)	Number of Patients (Tamoxifen)
15%	11%	Breast cancer	3,092	3,094

**Anastrozole: Adverse Reaction: Arthritis**
Drug (Anastrozole)	Comparator (Tamoxifen)	Indication	Number of Patients (Anastrozole)	Number of Patients (Tamoxifen)
17%	14%	Breast cancer	3,092	3,094

**Anastrozole: Adverse Reaction: Back Pain**
Drug (Anastrozole)	Comparator (Tamoxifen)	Indication	Number of Patients (Anastrozole)	Number of Patients (Tamoxifen)
12%	13%	Breast cancer	506	511
10%	10%	Breast cancer	3,092	3,094

**Anastrozole: Adverse Reaction: Ostealgia**
Drug (Anastrozole)	Comparator (Tamoxifen)	Indication	Number of Patients (Anastrozole)	Number of Patients (Tamoxifen)
11%	10%	Breast cancer	506	511
7%	6%	Breast cancer	3,092	3,094

**Anastrozole: Adverse Reaction: Osteoporosis**
Drug (Anastrozole)	Comparator (Tamoxifen)	Indication	Number of Patients (Anastrozole)	Number of Patients (Tamoxifen)
11%	7%	Breast cancer	3,092	3,094

Respiratory: Increased cough (8% to 11%), pharyngitis (6% to 14%)

1% to 10%:

Cardiovascular: Acute myocardial infarction (1% in patients with preexisting ischemic heart disease; 0.9%) (table 8), cerebral ischemia (2%), chest pain (5% to 7%), deep vein thrombosis (2%), edema (7%), peripheral edema (5% to 10%), thromboembolic disease (3% to 4%), thrombophlebitis (2% to 5%), venous thrombosis (3%)

**Anastrozole: Adverse Reaction: Acute Myocardial Infarction**
Drug (Anastrozole)	Comparator (Tamoxifen)	Indication	Number of Patients (Anastrozole)	Number of Patients (Tamoxifen)	Comments
1%	1%	Breast cancer	3,092	3,094	N/A
0.9%	3%	Breast cancer	216	249	In patients with preexisting ischemic heart disease

Dermatologic: Alopecia (2% to 5%), diaphoresis (2% to 5%), pruritus (2% to 5%)

Endocrine & metabolic: Hypercholesterolemia (9%), increased gamma-glutamyl transferase (2% to 5%), weight gain (2% to 9%), weight loss (2% to 5%)

Gastrointestinal: Abdominal pain (7% to 9%), anorexia (5% to 7%), constipation (7% to 9%), diarrhea (8% to 9%), dyspepsia (7%), gastrointestinal disease (7%), xerostomia (4% to 6%)

Genitourinary: Leukorrhea (2% to 3%), mastalgia (8%), pelvic pain (5%), urinary tract infection (8%), vaginal discharge (4%), vaginal dryness (2%), vaginal hemorrhage (1% to 5%), vaginitis (4%), vulvovaginitis (6%)

Hematologic & oncologic: Anemia (4%), leukopenia (2% to 5%), lymphedema (10%), neoplasm (5%), tumor flare (3%)

Hepatic: Increased serum alanine aminotransferase (2% to 5%), increased serum alkaline phosphatase (2% to 5%), increased serum aminotransferase (2% to 5%)

Infection: Infection (9%)

Nervous system: Anxiety (6%), carpal tunnel syndrome (3%) (table 9), confusion (2% to 5%), dizziness (6% to 8%), drowsiness (2% to 5%), hypertonia (3%), insomnia (6% to 10%), lethargy (1%), malaise (2% to 5%), nervousness (2% to 5%), paresthesia (5% to 7%)

**Anastrozole: Adverse Reaction: Carpal Tunnel Syndrome**
Drug (Anastrozole)	Comparator (Tamoxifen)	Indication	Number of Patients (Anastrozole)	Number of Patients (Tamoxifen)
3%	0.7%	Breast cancer	3,092	3,094

Neuromuscular & skeletal: Arthropathy (6% to 7%) (table 10), bone fracture (10%) (table 11), myalgia (6%) (table 12)Anastrozole: Adverse Reaction: Myalgia, neck pain (2% to 5%), pathological fracture (2% to 5%)

**Anastrozole: Adverse Reaction: Arthropathy**
Drug (Anastrozole)	Comparator (Tamoxifen)	Indication	Number of Patients (Anastrozole)	Number of Patients (Tamoxifen)	Comments
7%	5%	Breast cancer	3,092	3,094	Described in Arimidex PI 2018.12 as “arthrosis”
6%	5%	Breast cancer	3,092	3,094	Described in Arimidex PI 2018.12 as “joint disorder”

**Anastrozole: Adverse Reaction: Bone Fracture**
Drug (Anastrozole)	Comparator (Tamoxifen)	Indication	Number of Patients (Anastrozole)	Number of Patients (Tamoxifen)
10%	7%	Breast cancer	3,092	3,094

**Anastrozole: Adverse Reaction: Myalgia**
Drug (Anastrozole)	Comparator (Tamoxifen)	Indication	Number of Patients (Anastrozole)	Number of Patients (Tamoxifen)
6%	5%	Breast cancer	3,092	3,094

Ophthalmic: Cataract (6%)

Respiratory: Bronchitis (5%), dyspnea (8% to 10%), flu-like symptoms (6% to 7%), rhinitis (2% to 5%), sinusitis (6%)

Miscellaneous: Accidental injury (10%), cyst (5%), fever (2% to 5%)

<1%:

Dermatologic: Dermal ulcer, skin blister

Hematologic & oncologic: Endometrial carcinoma

Hepatic: Abnormal hepatic function tests, hepatitis, hepatomegaly, jaundice

Frequency not defined: Cardiovascular: Cerebral infarction (Sagara 2010), pulmonary embolism (Lycette 2006), retinal thrombosis (Eisner 2008)

Postmarketing:

Dermatologic: Dermatitis (Kim 2020), dermatologic disorder (lichen sclerosus) (Agrawal 2017; Potter 2013), erythema multiforme (Cozzani 2018; Wollina 2018), hypersensitivity angiitis (Shoda 2005), pruritic rash (Bremec 2009; Tanaka 2019), Stevens-Johnson syndrome, urticaria (Bock 2014), xeroderma (Cristofanilli 2010)

Endocrine & metabolic: Hypercalcemia (Järhult 2014; Yu 2016), hyperparathyroidism (Järhult 2014)

Hematologic & oncologic: Polycythemia (Kapoor 2019; Yeruva 2015)

Hepatic: Increased serum bilirubin, liver steatosis (Lacey 2014)

Hypersensitivity: Anaphylaxis, angioedema

Infection: Pulmonary cryptococcosis (Wei 2020)

Nervous system: Tardive dyskinesia (Manjunatha 2013)

Neuromuscular & skeletal: Decreased bone mineral density (common: ≥10%) (Eastell 2008; Markopoulos 2010), subacute cutaneous lupus erythematosus (Fisher 2016), tendinopathy (Martens 2007), tenosynovitis (stenosing)

Ophthalmic: Vitreous traction (Eisner 2008)

Contraindications

Hypersensitivity to anastrozole or any component of the formulation.

Canadian labeling: Additional contraindications (not in the US labeling): Pregnancy, breastfeeding.

Warnings/Precautions

Disease-related concerns:

• Hepatic impairment: Plasma concentrations in patients with stable hepatic cirrhosis were within the range of concentrations seen in normal subjects across all clinical trials.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Tablet, Oral:

Arimidex: 1 mg

Generic: 1 mg

Generic Equivalent Available: US

Yes

Pricing: US

Tablets (Anastrozole Oral)

1 mg (per each): $6.94 - $13.50

Tablets (Arimidex Oral)

1 mg (per each): $65.29

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Tablet, Oral:

Arimidex: 1 mg

Generic: 1 mg

Administration: Adult

Oral: May be administered with or without food.

Hazardous Drugs Handling Considerations

Hazardous agent (NIOSH 2016 [group 1]).

Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations and institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).

Use: Labeled Indications

Breast cancer:

First-line treatment of locally advanced or metastatic breast cancer (hormone receptor–positive or unknown) in postmenopausal patients.

Adjuvant treatment of early hormone receptor-positive breast cancer in postmenopausal patients.

Treatment of advanced breast cancer in postmenopausal patients with disease progression following tamoxifen therapy.

Use: Off-Label: Adult

Breast cancer, high-risk, hormone receptor–positive, adjuvant endocrine therapy in premenopausal patients (in combination with ovarian function suppression); Breast cancer in male patients, hormone receptor–positive; Endometrial or uterine cancers (recurrent or metastatic); Ovarian cancer (recurrent); Risk reduction for breast cancer in postmenopausal patients

Medication Safety Issues

Sound-alike/look-alike issues:

Anastrozole may be confused with anagrelide, letrozole

Arimidex may be confused with Aromasin

Metabolism/Transport Effects

None known.

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.

Estrogen Derivatives: May diminish the therapeutic effect of Anastrozole. Risk X: Avoid combination

Levomethadone: Aromatase Inhibitors may increase the serum concentration of Levomethadone. Risk C: Monitor therapy

Methadone: Aromatase Inhibitors may increase the serum concentration of Methadone. Risk C: Monitor therapy

Tamoxifen: May decrease the serum concentration of Anastrozole. Risk X: Avoid combination

Reproductive Considerations

Evaluate pregnancy status prior to therapy. Verify the patient is not pregnant prior to treatment initiation in patients who could become pregnant. Patients who could become pregnant should use effective contraception during therapy and for at least 3 weeks after the last anastrozole dose.

Pregnancy Considerations

Based on the mechanism of action and data from animal reproduction studies, anastrozole may cause fetal harm if exposure occurs during pregnancy.

Breastfeeding Considerations

It is not known if anastrozole is present in breast milk.

Due to the potential for serious adverse reactions in the breastfed infant, the manufacturer does not recommend breastfeeding during therapy or for 2 weeks after the last anastrozole dose.

Monitoring Parameters

Hormone-receptor status. Bone mineral density at baseline and periodically thereafter; total cholesterol and LDL. Pregnancy test (prior to treatment in patients who could become pregnant). Monitor adherence.

Breast cancer risk reduction (off-label use): Bone mineral density at baseline, mammograms, and clinical breast exam at baseline and at least every 2 years (Cuzick 2014).

Cardiovascular monitoring for patients with breast cancer: Comprehensive assessment prior to treatment including a history and physical examination, screening for cardiovascular disease risk factors such as hypertension, diabetes, dyslipidemia, obesity, and smoking; estimate 10-year cardiovascular disease risk in patients without cardiovascular disease at baseline; assess cardiovascular risk annually in patients with a high 10-year risk (ASCO [Armenian 2017]; ESC [Lyon 2022]).

Mechanism of Action

Anastrozole is a potent and selective nonsteroidal aromatase inhibitor. By inhibiting aromatase, the conversion of androstenedione to estrone, and testosterone to estradiol, is prevented, thereby decreasing tumor mass or delaying progression in patients with tumors responsive to hormones. Anastrozole causes an 85% decrease in estrone sulfate levels.

Pharmacokinetics (Adult Data Unless Noted)

Onset of estradiol reduction: 70% reduction after 24 hours; 80% after 2 weeks of therapy

Duration of estradiol reduction: 6 days

Absorption: Well absorbed; extent of absorption not affected by food

Protein binding, plasma: 40%

Metabolism: Extensively hepatic (~85%) via N-dealkylation, hydroxylation, and glucuronidation; primary metabolite (triazole) inactive

Half-life elimination: ~50 hours

Time to peak, plasma: ~2 hours without food; 5 hours with food

Excretion: Feces; urine (urinary excretion accounts for ~10% of total elimination, mostly as metabolites)

Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)

Altered kidney function: Renal clearance is decreased proportionally with CrCl and was approximately 50% lower in those with severe renal function impairment (CrCl less than 30 mL/minute per 1.73 m²); this reduced total body clearance by 10%.

Hepatic function impairment: Oral clearance was approximately 30% lower in those with stable hepatic cirrhosis, but plasma concentrations were within normal range.

Brand Names: International

International Brand Names by Country

For country code abbreviations (show table)

(AE) United Arab Emirates: Arimidex;
(AR) Argentina: Anastradex | Anastrazol rontag | Anastrozol glenmark | Anastrozol gp pharm | Anastrozol Kilab | Anebol | Arimidex | Cefer | Leprofen | Pantestone;
(AT) Austria: Anastro | Anastrolan | Anastrozol +pharma | Anastrozol 1 A Pharma | Anastrozol actavis | Anastrozol arcana | Anastrozol bluefish | Anastrozol genericon | Anastrozol Hikma | Anastrozol kabi | Anastrozol medico uno | Anastrozol Ranbaxy | Anastrozol ratiopharm | Anastrozol sandoz | Anastrozol Stada | Arimidex | Nastrin;
(AU) Australia: Anastrol | Anastrozole an | Anastrozole drla | Anastrozole fbm | Anastrozole ga | Anastrozole lw | Anastrozole ps | Anastrozole rbx | Anastrozole sandoz | Anastrozole synthon | Anzole | Apo anastrozole | Arianna | Arimidex | Astzol | Azastrole | Pharmacor anastrozole | Stada anastrozole | Terry white chemists anastrozole;
(BD) Bangladesh: Arimidex | Aromatin;
(BE) Belgium: Anastrarom | Anastrozol actavis | Anastrozol Apotex | Anastrozol sandoz | Anastrozole Accord | Anastrozole EG | Anastrozole Mylan | Anastrozole teva | Arimidex;
(BF) Burkina Faso: Anastrazole denk | Anatero | Arimidex;
(BG) Bulgaria: Anaromat | Anastrocon | Anastrogratis | Anastrozex | Arimidex | Armotraz | Kyaresta | Zenbrest;
(BR) Brazil: Anastrolibbs | Anastrozol | Anya | Arazabi | Arimidex | Trozolet;
(CH) Switzerland: Anastrozol actavis | Anastrozol devatis | Anastrozol Helvepharm | Anastrozol Mepha | Anastrozol Orion | Anastrozol sandoz | Anastrozol teva | Anastrozol zentiva | Arimidex;
(CI) Côte d'Ivoire: Anastrozole denk | Anatero | Arimidex;
(CL) Chile: Anastrozol | Anasvitae | Arimidex;
(CN) China: Ai da | Arimidex | Rui si yi | Rui ting;
(CO) Colombia: Aizol | Anana | Anastole | Anastrozol | Anastrozol denk | Armistraz | Hb oncocare | Prazolar | Trozolet;
(CZ) Czech Republic: Alozex | Anaprex | Anastar | Anastrad | Anastrozol | Anastrozol +pharma | Anastrozol actavis | Anastrozol Medac | Anastrozol Mylan | Anastrozol sandoz | Anastrozole grindeks | Anastrozole Medico Uno | Anastrozole Pharmacenter | Anastrozole teva | Anaya | Apo anastrozol | Arimidex | Asnea | Atrocela | Egistrozol | Mastoren | Oncofem | Zenbrest | Zynzol;
(DE) Germany: Anablock | Anadex | Anastro Cell | Anastrohexal | Anastromin | Anastropuren | Anastrozol | Anastrozol 1 A Pharma | Anastrozol Accord | Anastrozol acino | Anastrozol Acis | Anastrozol actavis | Anastrozol AL | Anastrozol amarox | Anastrozol aristo | Anastrozol Atid | Anastrozol axcount | Anastrozol Axios | Anastrozol Basic | Anastrozol Beta | Anastrozol biomo | Anastrozol bluefish | Anastrozol CT | Anastrozol denk | Anastrozol devatis | Anastrozol dura | Anastrozol Fair Med | Anastrozol glenmark | Anastrozol Heumann | Anastrozol Hormosan | Anastrozol kabi | Anastrozol Medicom | Anastrozol onkovis | Anastrozol Pfizer | Anastrozol Q | Anastrozol ratiopharm | Anastrozol Stada | Anastrozol Sun | Anastrozol teva | Anastrozol Winthrop | Arimidex | Eurostrozol | Ribomidex;
(DO) Dominican Republic: Amtraz | Anebol | Antrozol | Armotraz;
(EC) Ecuador: Anastrozol | Anasvitae | Anatero | Arimidex | Trozolet;
(EE) Estonia: Anastrozol ratiopharm | Anastrozole Accord | Anastrozole actavis | Anastrozole sandoz | Anastrozole Swiss | Anastrozole teva | Arimidex | Axastrol | Mammozole | Zynzol;
(EG) Egypt: Anastrodex | Anastrozol sandoz | Anastrozol Synthon | Anastrozole pharmacare | Arimidex;
(ES) Spain: Amenur | Anabrest | Anastrozol Accord | Anastrozol actavis | Anastrozol Apotex | Anastrozol aristo | Anastrozol bluefish | Anastrozol Cinfa | Anastrozol Combix | Anastrozol curaxys | Anastrozol Davur | Anastrozol Kern pharma | Anastrozol Mabo | Anastrozol Normon | Anastrozol Pensa | Anastrozol Pharmagenus | Anastrozol Ranbaxy | Anastrozol ratiopharm | Anastrozol sandoz | Anastrozol Stada | Anastrozol Tarbis | Anastrozol teva | Anastrozol UR | Anastrozol Vegal | Anastrozol Winthrop | Arimidex | Curmyl;
(ET) Ethiopia: Anastronat | Anastrozol sandoz | Anastrozole denk | Aremed | Arimidex | Womazole;
(FI) Finland: Anastelb | Anastrozol actavis | Anastrozol eql pharma | Anastrozol Medac | Anastrozol Mylan | Anastrozol Orifarm | Anastrozol Orion | Anastrozol Pensa | Anastrozol ratiopharm | Anastrozol sandoz | Anastrozol Stada | Anastrozol teva | Anastrozole bluefish | Anazol | Arimidex;
(FR) France: Anastrozole Accord | Anastrozole Almus | Anastrozole Alter | Anastrozole Arrow | Anastrozole biogaran | Anastrozole bluefish | Anastrozole cristers | Anastrozole EG | Anastrozole evolugen | Anastrozole gerda | Anastrozole Isomed | Anastrozole Mylan | Anastrozole Phr | Anastrozole ranbaxy | Anastrozole ratiopharm | Anastrozole sandoz | Anastrozole teva | Anastrozole Winthrop | Anastrozole Zydus | Arimidex;
(GB) United Kingdom: Arimidex | Nastrosa;
(GR) Greece: Anastrogen | Anastrozole teva | Anastrozole/Generics | Arimidex | Astrazol | Avomin | Enastros | Londer | Oxeda | Viastrol | Zolitrat;
(HK) Hong Kong: Aremed | Arimidex;
(HR) Croatia: Anastris | Anastrozol JGL | Anastrozol Pliva | Anastrozol sandoz | Aremed | Arimidex | Armotraz | Astralis | Azonet | Strazolan;
(HU) Hungary: Anamataz | Anaromat | Anastrozol +pharma | Anastrozol kabi | Anastrozol ratiopharm | Anastrozol sandoz | Anastrozol Stada | Anastrozole bluefish | Anastrozole medine | Anastrozole Pharmacenter | Arilla | Arimidex | Atrocela | Axastrol | Mammozole | Mastoren | Nobrec | Valmidex | Zynzol;
(ID) Indonesia: Anamidex | Arimidex | Bracer;
(IE) Ireland: Agerdex | Amidex | Anastrozole actavis | Anastrozole bluefish | Anastrozole Niche | Anastrozole teva | Arimidex;
(IL) Israel: Arimidex;
(IN) India: Adova | Altraz | Anabrez | Anaday | Anamit | Anastronat | Anastroz | Anazol | Anosam | Arimidex | Armotraz | Aromita | Avantaz | Elinal | Femistra | Lilmantro | Oncozole | Qubol | Stazonex | Trazocad | Xenosoul;
(IT) Italy: Adiunastrol | Anastrozolo | Anastrozolo accord healthcare | Anastrozolo actavis | Anastrozolo alter | Anastrozolo Bluefish | Anastrozolo doc generici | Anastrozolo mylan generics | Anastrozolo professionalcare | Anastrozolo sandoz | Anastrozolo Sun | Anastrozolo teva | Anastrozolo Winthrop | Arimidex | Extroplex | Ibistrazolo | Iniben | Keyfen | Renazole;
(JO) Jordan: Anarix | Aremed | Arimidex | Armotraz;
(JP) Japan: Anastrozole sn | Arimidex;
(KE) Kenya: Anastrazole denk | Anatero | Arimidex;
(KR) Korea, Republic of: A Dex | Anarozol | Anasprin | Anasto | Arimidex | Arimista | Atrozole | Femizet | Teva anastrozole;
(KW) Kuwait: Apo anastrozole | Arimidex;
(LB) Lebanon: Anastrazol vegal | Anastrozole biogaran | Anastrozole bluefish | Apo anastrozole | Arimidex | Victeve | Zortex;
(LT) Lithuania: Anastrozol actavis | Anastrozol ratiopharm | Anastrozole Accord | Anastrozole actiopharma | Anastrozole elvim | Anastrozole orion | Anastrozole sandoz | Anastrozole Sanoswiss | Anastrozole teva | Arimidex | Axastrol | Egistrozol | Mammozole | Zynzol;
(LU) Luxembourg: Anastrozol ratiopharm | Anastrozol sandoz | Anastrozole EG | Arimidex;
(LV) Latvia: Anastera | Anastrozole Accord | Anastrozole actavis | Anastrozole orion | Anastrozole sandoz | Anastrozole Sanoswiss | Anastrozole teva | Arimidex | Axastrol | Mammozole | Zenbrest | Zynzol;
(MA) Morocco: Anastrozole zenith | Arimidex | Aritrozole;
(MX) Mexico: Acetraz | Anasa | Anastrozol | Anastrozol Synthon | Anna | Arimidex | Asoinacor | Breazoc | Deramedra | Femistra | Femizet | Lapostim | Magemiv | Naztegan | Orminib | Poscirol | Probitor | Quifamider | Tamcevan | Treure | Ultrodena | Wisbulon | Zolasatin | Zurozol;
(MY) Malaysia: Anast | Ansuzole | Aremed | Arimidex | Armotraz | Dp anastrozole | Femizet;
(NL) Netherlands: Anastrozol | Anastrozol Accord | Anastrozol actavis | Anastrozol Apotex | Anastrozol bluefish | Anastrozol cf | Anastrozol focus | Anastrozol Mylan | Anastrozol pch | Anastrozol ratiopharm | Anastrozol sandoz | Anastrozol Sun | Anastrozol Synthon | Arimidex;
(NO) Norway: Anastrozol bluefish | Anastrozol Medac | Anastrozol medical valley | Anastrozol sandoz | Anastrozole teva | Arimidex;
(NZ) New Zealand: Anatrole | Aremed | Arimidex | Dp anastrozole | Rolin;
(PE) Peru: Anastrozol | Arimidex | Astrol;
(PH) Philippines: Anarom | Anastrozole Biomedis | Anatero | Anazole | Andrazole | Anzol | Aremed 1 | Arimidex | Armida | Sananas | Scitrozole | Strazol | Vexal A;
(PK) Pakistan: Adnast | Anabrec | Anastrozole belmed | Anastrozole sandoz | Anazole | Arimidex | Arimisol | Astrolex | Atzol | Femizet | Geneplex | Nastozol | Pantestone | Redest;
(PL) Poland: Anastralan | Anastrolek | Anastrozol Medac | Anastrozol ratiopharm | Anastrozol teva | Anastrozole Accord | Anastrozole Arrow | Anastrozole bluefish | Anastrozole orion | Apo nastrol | Arimidex | Atrozol | Egistrozol | Symanastrol | Zolastrol;
(PR) Puerto Rico: Arimidex;
(PT) Portugal: Anastrozol | Anastrozol Accord | Anastrozol actavis | Anastrozol farmoz | Anastrozol germed | Anastrozol Hikma | Anastrozol kabi | Anastrozol Mylan | Anastrozol Stada | Arimidex;
(PY) Paraguay: Anastrozol imedic | Anastrozol richmond | Arimidex;
(QA) Qatar: Anastralex | Arimidex;
(RO) Romania: Anaromat | Anastraze | Anastrozol atb | Anastrozol bluefish | Anastrozol kabi | Anastrozol terapia | Anastrozol teva | Anastrozole Medico Uno | Arimidex | Egistrozol | Eloza | Enzamidex | Kyaresta | Ozolan;
(RU) Russian Federation: Anabrez | Anastera | Anastrex | Anastrosol Kabi | Anastrozole kabi | Anastrozole teva | Anastrozole tl | Anazales | Arimidex | Axastrol | Egistrazole | Estarizol | Mammosole | Selana | Vero Anastrosol;
(SA) Saudi Arabia: Arimidex | Tabidex;
(SE) Sweden: Anastelb | Anastrozol abacus medicine | Anastrozol actavis | Anastrozol Arrow | Anastrozol Campus | Anastrozol ebb | Anastrozol eql pharma | Anastrozol Medac | Anastrozol medical valley | Anastrozol Mylan | Anastrozol Orifarm | Anastrozol Pensa | Anastrozol sandoz | Anastrozole 2care4 | Anastrozole Accord | Anastrozole bluefish | Anastrozole mds | Anastrozole teva | Arimidex;
(SG) Singapore: Arimidex;
(SI) Slovenia: Anastrozol lek | Anastrozol teva | Arimidex;
(SK) Slovakia: Anaprex | Anastelb | Anastrozol +pharma | Anastrozol ebewe | Anastrozol sandoz | Anastrozole bluefish | Anastrozole grindeks | Anastrozole Medico Uno | Anastrozole Pharmacenter | Arimidex | Asnea | Ozolan | Zenbrest;
(TH) Thailand: Anastrozole sandoz | Aremed | Arimidex | Femizet;
(TN) Tunisia: Anastra | Anastrodex | Anastrozole zentiva | Avomin;
(TR) Turkey: Anazol | Arimidex | Aristu | Santra | Veridex;
(TW) Taiwan: Anazo | Anotrole | Aremed | Arimidex;
(UA) Ukraine: Actastrozol | Anastera | Anastrozol sandoz | Anastrozol vista | Anatero | Arimidex | Axastrol | Egistrozol;
(UG) Uganda: Anastrozole denk | Anatero | Arimidex | Womazole;
(UY) Uruguay: Anastrol | Anastrozol | Arimidex | Pantestone | Trozolet;
(VE) Venezuela, Bolivarian Republic of: Anastwin | Arimidex | Trozolet;
(VN) Viet Nam: Aritrodex | Asstrozol;
(ZA) South Africa: Accord anastrozole | Anabrez | Anastrozole sandoz | Arimidex | Castra | Everdex | Mylan Anastrozole | Stradexa | Teva anastrozole;
(ZM) Zambia: Anastrozole denk | Anatero | Arimidex;
(ZW) Zimbabwe: Anatero | Arimidex

<800> Hazardous Drugs–Handling in Healthcare Settings. United States Pharmacopeia and National Formulary (USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.
Agrawal C, Pradeep Babu KV, Dash PK, Saini R. Oral lichen sclerosus in a breast cancer patient on anastrozole therapy: a case report with brief review of literature. Arch Med Health Sci. 2017;5:245‑247.
Amir E, Seruga B, Niraula S, Carlsson L, Ocaña A. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. J Natl Cancer Inst. 2011;103(17):1299-1309. doi:10.1093/jnci/djr242 [PubMed 21743022]
Arimidex (anastrozole) [prescribing information]. Baudette, MN: ANI Pharmaceuticals; December 2018.
Arimidex (anastrozole) [product monograph]. Mississauga, Ontario, Canada: AstraZeneca Canada Inc; November 2022.
Armenian SH, Lacchetti C, Barac A, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2017;35(8):893-911. doi:10.1200/JCO.2016.70.5400 [PubMed 27918725]
Bock VL, Friedlander M, Waring D, Kossard S, Wood GK. Cutaneous adverse effects of hormonal adjuvant therapy for breast cancer: a case of localised urticarial vasculitis following anastrozole therapy and a review of the literature. Australas J Dermatol. 2014;55(4):282-285. doi:10.1111/ajd.12110 [PubMed 24575835]
Borrie AE, Rose FA, Choi YH, et al. Genetic and clinical predictors of arthralgia during letrozole or anastrozole therapy in breast cancer patients. Breast Cancer Res Treat. 2020;183(2):365-372. doi:10.1007/s10549-020-05777-1 [PubMed 32632513]
Bremec T, Demsar J, Luzar B, Pavlović MD. Drug-induced pruritic micropapular eruption: anastrozole, a commonly used aromatase inhibitor. Dermatol Online J. 2009;15(7):14. [PubMed 19903442]
Burstein HJ, Lacchetti C, Anderson H, et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: ASCO clinical practice guideline focused update. J Clin Oncol. 2019;37(5):423-438. doi:10.1200/JCO.18.01160 [PubMed 30452337]
Burstein HJ, Lacchetti C, Anderson H, et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: ASCO clinical practice guideline update on ovarian suppression. J Clin Oncol. 2016;34(14):1689-1701. doi:10.1200/JCO.2015.65.9573 [PubMed 26884586]
Buzdar A, Howell A, Cuzick J, et al; Arimidex, Tamoxifen, Alone or in Combination Trialists' Group. Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol. 2006;7(8):633-643. doi:10.1016/S1470-2045(06)70767-7 [PubMed 16887480]
Buzdar AU, Robertson JF, Eiermann W, Nabholtz JM. An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane. Cancer. 2002;95(9):2006-2016. doi: 10.1002/cncr.10908. [PubMed 12404296]
Cozzani E, Trave I, Burlando M, Parodi A. Erythematous maculopapular eruption induced by anastrozole: the first case. Am J Ther. 2018;25(6):e743-e744. doi:10.1097/MJT.0000000000000755 [PubMed 29668491]
Crew KD, Greenlee H, Capodice J, et al. Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol. 2007;25(25):3877-3883. doi:10.1200/JCO.2007.10.7573 [PubMed 17761973]
Cristofanilli M, Valero V, Mangalik A, et al. Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer. Clin Cancer Res. 2010;16(6):1904-1914. doi:10.1158/1078-0432.CCR-09-2282 [PubMed 20215537]
Cuzick J, Sestak I, Forbes JF, et al. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet. 2014;383(9922):1041-1048. doi: 10.1016/S0140-6736(13)62292-8 [PubMed 24333009]
del Carmen MG, Fuller AF, Matulonis U, et al. Phase II trial of anastrozole in women with asymptomatic müllerian cancer. Gynecol Oncol. 2003;91(3):596-602. [PubMed 14675683]
Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials. Lancet Oncol. 2022;23(3):382-392. doi:10.1016/S1470-2045(21)00758-0 [PubMed 35123662]
Eastell R, Adams J, Clack G, et al. Long-term effects of anastrozole on bone mineral density: 7-year results from the ATAC trial. Ann Oncol. 2011;22(4):857-862. doi:10.1093/annonc/mdq541 [PubMed 20929964]
Eastell R, Adams JE, Coleman RE, et al. Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. J Clin Oncol. 2008;26(7):1051-1057. doi: 10.1200/JCO.2007.11.0726 [PubMed 18309940]
Eisner A, Falardeau J, Toomey MD, Vetto JT. Retinal hemorrhages in anastrozole users. Optom Vis Sci. 2008;85(5):301-308. doi:10.1097/OPX.0b013e31816bea3b [PubMed 18451730]
Felson DT, Cummings SR. Aromatase inhibitors and the syndrome of arthralgias with estrogen deprivation. Arthritis Rheum. 2005;52(9):2594-2598. doi:10.1002/art.21364 [PubMed 16142740]
Finn RS, Martin M, Rugo HS, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016;375(20):1925-1936. doi:10.1056/NEJMoa1607303 [PubMed 27959613]
Fisher J, Patel M, Miller M, Burris K. Anastrozole-induced subacute cutaneous lupus erythematosus. Cutis. 2016;98(2):E22–E26. [PubMed 27622265]
Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS, Baum M; Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists' Group. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol. 2008;9(1):45-53. doi: 10.1016/S1470-2045(07)70385-6 [PubMed 18083636]
Gaillard S, Stearns V. Aromatase inhibitor-associated bone and musculoskeletal effects: new evidence defining etiology and strategies for management. Breast Cancer Res. 2011;13(2):205. doi:10.1186/bcr2818 [PubMed 21457526]
Gnant M, Mlineritsch B, Stoeger H, et al; Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria. Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozole plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12. Ann Oncol. 2015;26(2):313-320. doi:10.1093/annonc/mdu544 [PubMed 25403582]
Goetz MP, Toi M, Campone M, et al. MONARCH 3: Abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol. 2017;35(32):3638-3646. doi: 10.1200/JCO.2017.75.6155 [PubMed 28968163]
Goldvaser H, Barnes TA, Šeruga B, et al. Toxicity of extended adjuvant therapy with aromatase inhibitors in early breast cancer: a systematic review and meta-analysis. J Natl Cancer Inst. 2018;110(1):10.1093/jnci/djx141. doi:10.1093/jnci/djx141 [PubMed 28922781]
Goss PE, Ingle JN, Pritchard KI, et al. Extending aromatase-inhibitor adjuvant therapy to 10 years. N Engl J Med. 2016;375(3):209-219. doi: 10.1056/NEJMoa1604700 [PubMed 27264120]
Hadji P, Aapro MS, Body JJ, et al. Management of aromatase inhibitor-associated bone loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG. J Bone Oncol. 2017;7:1-12. doi:10.1016/j.jbo.2017.03.001 [PubMed 28413771]
Hadji P, Body JJ, Aapro MS, et al. Practical guidance for the management of aromatase inhibitor-associated bone loss. Ann Oncol. 2008;19(8):1407-1416. doi:10.1093/annonc/mdn164 [PubMed 18448451]
Haque R, Shi J, Schottinger JE, et al. Cardiovascular disease after aromatase inhibitor use. JAMA Oncol. 2016;2(12):1590-1597. doi:10.1001/jamaoncol.2016.0429 [PubMed 27100398]
Hassett MJ, Somerfield MR, Baker ER, et al. Management of male breast cancer: ASCO guideline. J Clin Oncol. 2020;38(16):1849-1863. doi:10.1200/JCO.19.03120 [PubMed 32058842]
Henry NL, Giles JT, Ang D, et al. Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors. Breast Cancer Res Treat. 2008;111(2):365-372. doi:10.1007/s10549-007-9774-6 [PubMed 17922185]
Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet. 2005;365(9453):60-62. doi:10.1016/S0140-6736(04)17666-6 [PubMed 15639680]
Järhult J. Anastrozole can cause severe hypercalcaemia mimicking primary hyperparathyroidism. Breast Cancer. 2014;21(3):379-381. doi:10.1007/s12282-011-0253-x [PubMed 21290264]
Jenkins VA, Ambroisine LM, Atkins L, Cuzick J, Howell A, Fallowfield LJ. Effects of anastrozole on cognitive performance in postmenopausal women: a randomised, double-blind chemoprevention trial (IBIS II). Lancet Oncol. 2008;9(10):953-961. doi: 10.1016/S1470-2045(08)70207-9 [PubMed 18768369]
Kamaraju S, Shi Y, Smith E, Nattinger AB, Laud P, Neuner J. Are aromatase inhibitors associated with higher myocardial infarction risk in breast cancer patients? A Medicare population-based study. Clin Cardiol. 2019;42(1):93-100. doi:10.1002/clc.23114 [PubMed 30443921]
Kapoor J, Singh N, Agrawal N, Ahmed R, Bhurani D. A case of anastrozole-induced erythrocytosis. Indian J Hematol Blood Transfus. 2019;35(1):194-195. doi:10.1007/s12288-018-1022-1 [PubMed 30828176]
Kaufmann M, Jonat W, Hilfrich J, et al. Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 Study. J Clin Oncol. 2007;25(19):2664-2670. doi: 10.1200/JCO.2006.08.8054 [PubMed 17563395]
Kendall A, Dowsett M, Folkerd E, Smith I. Caution: Vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors. Ann Oncol. 2006;17(4):584-587. doi: 10.1093/annonc/mdj127 [PubMed 16443612]
Kim YJ, Cohen PR. Anastrozole-induced dermatitis: report of a woman with an anastrozole-associated dermatosis and a review of aromatase inhibitor-related cutaneous adversee Events. Dermatol Ther (Heidelb). 2020;10(1):221-229. doi:10.1007/s13555-020-00353-3 [PubMed 31965545]
Köberle D, Thürlimann B. Anastrozole: pharmacological and clinical profile in postmenopausal women with breast cancer. Expert Rev Anticancer Ther. 2001;1(2):169-176. doi:10.1586/14737140.1.2.169 [PubMed 12113022]
Krens SD, Lassche G, Jansman FGA, et al. Dose recommendations for anticancer drugs in patients with renal or hepatic impairment. Lancet Oncol. 2019;20(4):e200-e207. doi:10.1016/S1470-2045(19)30145-7 [PubMed 30942181]
Lacey R, Evans A. An unusual cause of jaundice in a patient with breast cancer. BMJ Case Rep. 2014;2014:bcr2014205764. doi:10.1136/bcr-2014-205764 [PubMed 25540208]
Lønning PE, Geisler J, Dowsett M. Pharmacological and clinical profile of anastrozole. Breast Cancer Res Treat. 1998;49(suppl 1):S53-S57. [PubMed 9797018]
Lønning P, Pfister C, Martoni A, Zamagni C. Pharmacokinetics of third-generation aromatase inhibitors. Semin Oncol. 2003;30(4)(suppl 14):23-32. [PubMed 14513434]
Lycette JL, Luoh SW, Beer TM, Deloughery TG. Acute bilateral pulmonary emboli occurring while on adjuvant aromatase inhibitor therapy with anastrozole: Case report and review of the literature. Breast Cancer Res Treat. 2006;99(3):249-255. doi:10.1007/s10549-006-9212-1 [PubMed 16752073]
Lyon AR, López-Fernández T, Couch LS, et al; ESC Scientific Document Group. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022;43(41):4229-4361. doi:10.1093/eurheartj/ehac244 [PubMed 36017568]
Manjunatha N, Ganjekar S, Mahendra JV, Kilara N, Srinivasa R. Tardive dyskinesia associated with anastrozole. J Neuropsychiatry Clin Neurosci. 2013;25(3):E27-E28. doi:10.1176/appi.neuropsych.12060159 [PubMed 24026733]
Markopoulos C, Tzoracoleftherakis E, Polychronis A, et al. Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial. Breast Cancer Res. 2010;12(2):R24. doi:10.1186/bcr2565 [PubMed 20398352]
Martens HA, Schröder CP, van der Eerden PJ, Willemse PH, Posthumus MD. Severe disabling tendinopathy caused by anastrazole. Rheumatology (Oxford). 2007;46(10):1619-1621. doi:10.1093/rheumatology/kem213 [PubMed 17726034]
Matthews A, Stanway S, Farmer RE, et al. Long term adjuvant endocrine therapy and risk of cardiovascular disease in female breast cancer survivors: systematic review. BMJ. 2018;363:k3845. doi:10.1136/bmj.k3845 [PubMed 30297439]
National Osteoporosis Foundation. Clinician's Guide to Prevention and Treatment of Osteoporosis. Washington, DC; 2014. http://nof.org/files/nof/public/content/file/2791/upload/919.pdf.
Niravath P. Aromatase inhibitor-induced arthralgia: a review. Ann Oncol. 2013;24(6):1443-1449. doi:10.1093/annonc/mdt037 [PubMed 23471104]
Njar VC, Brodie AM. Comprehensive pharmacology and clinical efficacy of aromatase inhibitors. Drugs. 1999;58(2):233-255. doi: 10.2165/00003495-199958020-00003 [PubMed 10473018]
O'Cearbhaill R, Zhou Q, Iasonos A, et al. Treatment of advanced uterine leiomyosarcoma with aromatase inhibitors. Gynecol Oncol. 2010;116(3):424-429. [PubMed 19932916]
O'Shaughnessy J, Petrakova K, Sonke GS, et al. Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2- advanced breast cancer in the randomized MONALEESA-2 trial. Breast Cancer Res Treat. 2018;168(1):127-134. doi:10.1007/s10549-017-4518-8 [PubMed 29164421]
Potter JE, Moore KA. Lichen sclerosus in a breast cancer survivor on an aromatase inhibitor: a case report. J Gen Intern Med. 2013;28(4):592-595. doi:10.1007/s11606-012-2209-z [PubMed 22956445]
Presant CA, Bosserman L, Young T, et al. Aromatase inhibitor-associated arthralgia and/ or bone pain: frequency and characterization in non-clinical trial patients. Clin Breast Cancer. 2007;7(10):775-778. doi:10.3816/CBC.2007.n.038 [PubMed 18021478]
Puhalla S, Brufsky A, Davidson N. Adjuvant endocrine therapy for premenopausal women with breast cancer. Breast. 2009;18(suppl 3):S122-S130. doi: 10.1016/S0960-9776(09)70286-3 [PubMed 19914530]
Rose PG, Brunetto VL, VanLe L, Bell J, Walker JL, Lee RB. A phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2000;78(2):212-216. doi: 10.1006/gyno.2000.5865 [PubMed 10926805]
Sagara Y, Kosha S, Baba S, et al. Adverse events and bone health during anastrozole therapy in postmenopausal Japanese breast cancer patients. Breast Cancer. 2010;17(3):212-217. doi:10.1007/s12282-009-0135-7 [PubMed 19526308]
Sestak I, Cuzick J, Sapunar F, et al. Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis. Lancet Oncol. 2008;9(9):866-872. doi:10.1016/S1470-2045(08)70182-7 [PubMed 18703382]
Sestak I, Sapunar F, Cuzick J. Aromatase inhibitor-induced carpal tunnel syndrome: results from the ATAC trial. J Clin Oncol. 2009;27(30):4961-4965. doi:10.1200/JCO.2009.22.0236 [PubMed 19752338]
Shoda H, Inokuma S, Yajima N, Tanaka Y, Setoguchi K. Cutaneous vasculitis developed in a patient with breast cancer undergoing aromatase inhibitor treatment. Ann Rheum Dis. 2005;64(4):651-652. doi:10.1136/ard.2004.023150 [PubMed 15769928]
Smith YR, Stohler CS, Nichols TE, Bueller JA, Koeppe RA, Zubieta JK. Pronociceptive and antinociceptive effects of estradiol through endogenous opioid neurotransmission in women. J Neurosci. 2006;26(21):5777-5785. doi:10.1523/JNEUROSCI.5223-05.2006 [PubMed 16723535]
Spagnolo F, Sestak I, Howell A, Forbes JF, Cuzick J. Anastrozole-induced carpal tunnel syndrome: results from the international breast cancer intervention study II prevention trial. J Clin Oncol. 2016;34(2):139-143. doi:10.1200/JCO.2015.63.4972 [PubMed 26598748]
Tanaka A, Yamashita C, Hinogami H, Shirai H, Yamamura J, Ito R. Localized cutaneous adverse event induced by anastrozole as adjuvant treatment for breast cancer: a case report. Case Rep Dermatol. 2019;11(1):57-63. doi:10.1159/000497469 [PubMed 31011314]
Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143-3421. [PubMed 12485966]
Tripathy D, Im SA, Colleoni M, et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol. 2018;19(7):904-915. doi: 10.1016/S1470-2045(18)30292-4 [PubMed 29804902]
US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. https://www.cdc.gov/niosh/docs/2016-161/default.html. Updated September 2016. Accessed October 31, 2016.
van Hellemond IEG, Smorenburg CH, Peer PGM, et al. Assessment and management of bone health in women with early breast cancer receiving endocrine treatment in the DATA study. Int J Cancer. 2019;145(5):1325-1333. doi:10.1002/ijc.32205 [PubMed 30748011]
Visvanathan K, Fabian CJ, Bantug E, et al. Use of endocrine therapy for breast cancer risk reduction: ASCO clinical practice guideline update. J Clin Oncol. 2019;37(33):3152-3165. doi:10.1200/JCO.19.01472 [PubMed 31479306]
Wei M, Xu YR, Liu K, Wen P. Anastrozole-induced pulmonary cryptococcosis in a patient with early breast cancer: a case report. Medicine (Baltimore). 2020;99(2):e18688. doi:10.1097/MD.0000000000018688 [PubMed 31914067]
Wollina U, Schönlebe J, Heinig B, Tchernev G, França K, Lotti T. Segmental erythema multiforme-like drug eruption by aromatase inhibitor anastrozole - first case report and another example of an immunocompromised district. Open Access Maced J Med Sci. 2018;6(1):79-81. doi:10.3889/oamjms.2018.026 [PubMed 29483990]
Yeruva SL, Nwabudike SM, Ogbonna OH, Oneal P. Aromatase inhibitor-induced erythrocytosis in a patient undergoing hormonal treatment for breast cancer. Case Rep Hematol. 2015;2015:784783. doi:10.1155/2015/784783 [PubMed 26137331]
Yu R. Hypercalcemic crisis associated with anastrozole use in a patient with breast cancer and primary hyperparathyroidism. Endocrine. 2016;53(3):868-869. doi:10.1007/s12020-016-1006-6 [PubMed 27369187]
Zagouri F, Sergentanis TN, Azim HA Jr, et al. Aromatase inhibitors in male breast cancer: a pooled analysis. Breast Cancer Res Treat. 2015;151(1):141-147. doi:10.1007/s10549-015-3356-9 [PubMed 25850534]
Zagouri F, Sergentanis TN, Koutoulidis V, et al. Aromatase inhibitors with or without gonadotropin-releasing hormone analogue in metastatic male breast cancer: a case series. Br J Cancer. 2013;108(11):2259-2263. doi:10.1038/bjc.2013.255 [PubMed 23722469]

Topic 8780 Version 344.0

خرید پکیج

Anastrozole: Drug information